This report provides comprehensive information on the current therapeutic developmental pipeline of Agile Therapeutics, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Agile Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries- The report reviews current pipeline of Agile Therapeutics, Inc.’s human therapeutic division and enlists all their major and minor projects- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones - Special feature on out-licensed and partnered product portfolio- The report summarizes all the dormant and discontinued pipeline projects- Latest company statement - Latest news and deals relating to the Agile Therapeutics, Inc.’s pipeline products

Reasons to buy

- Evaluate Agile Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline- Assess the growth potential of Agile Therapeutics, Inc. in its therapy areas of focus- Identify new drug targets and therapeutic classes in the Agile Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps- Develop strategic initiatives by understanding the focus areas of Agile Therapeutics, Inc. and exploit collaboration and partnership opportunities- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Agile Therapeutics, Inc.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope- Explore the dormant and discontinued projects of Agile Therapeutics, Inc. and identify potential opportunities in those areas- Avoid Intellectual Property Rights related issues

Parent Industry

The Global Infectious Vaccines Partnering Terms and Agreements 2012 to 2018: Deal trends, players and financials report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right...

Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H2 2018 Summary Toll Like Receptor 3 (CD283 or TLR3) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Toll Like...

Kinase-targeted cancer therapies became really big with imatinib (Gleevec), a landmark drug that has vastly improved the outcomes of patients with chronic myelogenous leukemia. With the human genome encoding 538 protein kinases and many of these kinases being associated with human cancer initiation and progression, this field carries a lot...